article thumbnail

Does rosuvastatin cause hair loss?

The Checkup by Singlecare

In a 2002 report , a 38-year-old woman reported hair loss about six weeks after starting atorvastatin ( Lipitor ). Recent research describes a 53-year-old man who began to notice hair loss one week after starting rosuvastatin. He eventually stopped taking the medication, and his hair started to grow back one week later.

article thumbnail

Sustainable Alternative: PFAS-Free-TPE for Pharmaceutical Stoppers

PharmTech

Conclusion TPEs in medical applications, such as pharmaceutical stoppers for injection and medication vials, will drive material change in the coming years and—especially PFAS-free—are the alternative of the future. References 1. Annex 9 Introductory Note, Paragraph 8, Guidelines on Packaging for Pharmaceutical Products. Section 3.2.9 link] 4.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medication Adherence in 2025: The Hidden Crisis Costing Lives and Billions

PharmD Live

New England Journal of Medicine, 365 (21), 2002–2012. Lovegrove, M. Shehab, N., & Richards, C. Emergency hospitalizations for adverse drug events in older Americans. link] Centers for Medicare & Medicaid Services. Medicare star ratings technical notes. link] OECD. Health at a glance 2019: OECD indicators. OECD Publishing.

article thumbnail

Graduate Student Funding

Blog: Ask a Student Pharmacist

History National Dean Search Job Opportunities Giving to the College of Pharmacy Contact Degrees & Programs Degrees and Programs Overview Doctor of Pharmacy Dual Degree Programs Graduate Programs Medical Laboratory Sciences Program Occupational Therapy Program Postgraduate Pharmacy Residency Program Postgraduate Pharmacy Residency Program Overview (..)

article thumbnail

Can Breast Implants Trigger Hashimoto’s?

The Thyroid Pharmacist

Still, the demand was huge, and the number of breast implant surgeries increased by 72 percent from 1992 to 1996, and 147 percent from 1997 to 2002. [4] [3] The Problem with Saline Once silicone implants were outlawed, only saline implants were left as an option for women seeking breast augmentation.

article thumbnail

FDA green lights CSL's once-monthly HAE drug Andembry

pharmaphorum

Other competitors are on the horizon, including Intellias gene-editing drug lonvoguran ziclumeran (formerly NTLA-2002 ) that could offer a one-shot strategy for long-term protection against HAE attacks and recently started phase 3 testing.

FDA
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Theravance estimates that its lifetime earnings from GSK's inhaler Trelegy, born out of a 2002 collab, total $1.52